BLI-800-302: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
Launched by BRAINTREE LABORATORIES · Jul 18, 2007
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- -Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication, including:
- • Evaluation of BE results GI bleeding Anemia of unknown etiology Neoplastic disease surveillance Endosonography Inflammatory bowel disease Unknown diarrhea or constipation etiology Polypectomy Laser therapy Routine Screening
- • At least 18 years of age
- • Otherwise in good health, as determined by physical exam and medical history
- • If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, abstinent, or vasectomized spouse)
- • Negative urine pregnancy test at screening, if applicable
- • In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study
- Exclusion Criteria:
- • Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
- • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
- • Subjects who are undergoing colonoscopy for foreign body removal and decompression.
- • Subjects with clinically significant electrolyte abnormalities based on Visit 1 laboratory results, such as hypernatremia, hyponatremia, hyperphosphatemia, hypokalemia, hypocalcemia, dehydration, or those secondary to the use of diuretics or angiotensin converting enzyme (ACE) inhibitors.
- • Subjects with a history of renal or hepatic insufficiency or congestive heart failure.
- • Subjects who had previous gastrointestinal surgeries
- • Subjects who are pregnant or lactating, or intending to become pregnant during the study.
- • Subjects of childbearing potential who refuse a pregnancy test.
- • Subjects who are allergic to any preparation components
- • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
- • Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days.
About Braintree Laboratories
Braintree Laboratories is a leading clinical trial sponsor dedicated to advancing medical research and innovation in the pharmaceutical and biotechnology sectors. With a strong commitment to developing high-quality, safe, and effective therapies, Braintree Laboratories collaborates with healthcare professionals and research institutions to design and conduct rigorous clinical trials. The organization specializes in a wide range of therapeutic areas and employs state-of-the-art methodologies to ensure the integrity and reliability of trial results. Braintree Laboratories is focused on improving patient outcomes and contributing to the global healthcare landscape through its dedication to scientific excellence and ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Germantown, Tennessee, United States
Bellevue, Washington, United States
Houston, Texas, United States
Anaheim, California, United States
Orange, California, United States
Jackson, Mississippi, United States
Franklin, Ohio, United States
Portland, Oregon, United States
Patients applied
Trial Officials
John D McGowan, B.S.
Study Director
Braintree Laboratories, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials